Market Overview

UPDATE: Bank of America Downgrades Mindray Medical to Neutral Following Disappointing 1Q13 Results

Related MR
UPDATE: Jefferies Assumes Coverage On Mindray Medical International Ltd. On Moderate Growth Prospects
Mindray Medical Misses on Q1 Earnings - Analyst Blog

In a report published Wednesday, Bank of America analyst Serena Shao downgraded the rating on Mindray Medical International Ltd. (NYSE: MR) from Buy to Neutral, and lowered the price target from $39.50 to $38.00.

In the report, Shao noted, “Mindray reported a disappointing 1Q13 Result with Sales/ Earnings (non GAAP adjusted) missing consensus by -6%/ -10% respectively. The weak performance is mainly due to emerging market sales being disrupted by currency fluctuations and tougher import policies as well as political instability; with revenue growth in these industries flat during 1Q. As these regions accounted for ~30% of total sales and have enjoyed more than 20%+ growth in the past (historical data in Table 2), we believe this is a significant and fundamental change for Mindray's business stemming from the risk of greater growth reliance coming from these markets.”

Mindray Medical International Ltd. closed on Tuesday at $37.42.

Posted-In: Bank of AmericaAnalyst Color Downgrades Analyst Ratings


Most Popular

Related Articles (MR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free